Would you consider the use of EGFR inhibition (cetuximab/panitumumab) in first line in metastatic right-sided RAS/RAF WT colon cancer, if bevacizumab contraindicated?
Answer from: Medical Oncologist at Academic Institution
This is an area where I’ve seen practice patterns diverge amongst practitioners, even within the same institute, and has been subject to some lengthy discussions within our tumor boards. For me, the short answer is that in general, no, I would not give anti-EGFR to a patient with a right-...
Comments
Medical Oncologist at Montefiore Einstein Cancer Center Thanks. Why do we still do it in 2L? We don't have...
Medical Oncologist at UPMC Hillman Cancer Center That's a really great question - again, this is an...
Medical Oncologist at Montefiore Einstein Cancer Center Thank you!
Answer from: Medical Oncologist at Academic Institution
The use of EGFR inhibitors here might depend on what the goal is.
Is the goal conversion therapy to render someone resectable? And/or need for response?
I’d also like to know if the contra-indication to BEV is relative versus absolute.
There’s biological rationale in someone truly RAS...
Answer from: Medical Oncologist at Academic Institution
Studies in this setting are retrospective and metanalysis type in nature. I am not convinced that right-sided tumors do not benefit especially if RAS wild-type. Studies including CALGB/SWOG 80405, CRYSTAL and FIRE-3, have shown that among patients with KRAS wt untreated advanced or metastatic c...
Thanks. Why do we still do it in 2L? We don't have...
That's a really great question - again, this is an...
Thank you!